You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美药监部门近廿年来首度批准阿兹海默症新药 Biogen股价飙38%
阿思达克 06-08 10:32
美国食品及药物管理局(FDA)批准使用渤健(Biogen)(BIIB.US)研发的阿兹海默症(即老人痴呆症)新药aducanumab,为近二十年来首款获批准使用的阿兹海默症药物。当局将在药物於美国上市後持续监察,又在批准使用许可中加入条件,要求渤健进行另一次临床测试。。

渤健表示,有关药物表列价为每年剂量5.6万美元,每剂量4,312美元。公司行政总裁Michel Vounatsos指药物定价合理,又承诺公司四年内不会上调该药药价。

渤健股价昨日(8日)急升38.3%,报395.85美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account